Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Theralink(R) and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4
2:15 PM ET 11/13/23 | GlobeNewswire
Theralink(R) and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4
Golden, Colorado & Nashville, Tennessee, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) ("Theralink"), a precision oncology company with its exclusive commercial RPPA (reverse phase protein array) technology that can help predict which FDA-approved drug is effective in each cancer, today with its merger partner, IMAC Holdings, INC (Nasdaq: BACK), announce that the companies have responded to the SEC's first round of comments on the jointly filed form S-4. A Form S-4 is a registration statement that the Securities and Exchange Commission requires all reporting companies to file in order to publicly offer new securities pursuant to a merger or acquisition. The Companies previously filed the S-4 on September 29(th) and received comments from the SEC in late October.
Theralink's Chief Executive Officer, Faith Zaslavsky previously stated "The filing of the Form S-4 is a major milestone, as it signifies Theralink and IMAC have reached a definitive agreement and that the transaction is moving forward. The result of the Merger will be a well-positioned proteomics pure play squarely focused on the next generation of cancer care and protein analysis, an opportunity that all stakeholders in our companies are highly excited about. I am unaware of any other proteomics company with a robust patent estate, certified and accredited laboratory, and reimbursement agreements in place with major payors like Medicare that parallels what our new combined company possesses along with the leadership to execute and build value."
The companies expect to hear back from the Securities and Exchange Commission within the next 10 business days.
About Theralink Technologies, Inc.
Theralink Technologies is a proteomics-based, precision medicine company with a nationally CLIA-certified and CAP-accredited laboratory located in Golden, Colorado. Through its unique and patented phosphoprotein and protein biomarker platform and LDTs, Theralink's technology targets multiple areas of oncology and drug development. In addition to the Company's first assay for advanced breast cancer, Theralink is actively working on a second assay that is planned to be pan-tumor for solid tumors across multiple tumor types such as ovarian, endometrial, pancreatic, liver, head and neck, colorectal, lung, prostate, among others. Theralink provides precision oncology data through its powerful Theralink(R) Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. Theralink intends to help improve cancer outcomes for patients, help reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.
Theralink Technologies, Inc. (OTC: THER) ("Theralink") and IMAC Holdings, Inc. (Nasdaq: BACK) have entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") under which Theralink will merge with a newly formed, wholly-owned subsidiary of IMAC in a stock-for-stock reverse merger transaction (the "Merger") in which Theralink will survive as a wholly-owned subsidiary of IMAC, a Nasdaq-listed company. If completed, the Merger will result in a combined company that will focus on end-to-end proteomics testing, one of the most robust and growing areas of medicine.
Theralink Technologies, Inc. (OTC: THER) ("Theralink") and IMAC Holdings, Inc. (Nasdaq: BACK) have entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") under which Theralink will merge with a newly formed, wholly-owned subsidiary of IMAC in a stock-for-stock reverse merger transaction (the "Merger") in which Theralink will survive as a wholly-owned subsidiary of IMAC, a Nasdaq-listed company. If completed, the Merger will result in a combined company that will focus on end-to-end proteomics testing, one of the most robust and growing areas of medicine.
Going to be in cents soon..may be next week.
Good news...with nasdaq merger
THER STOCK..WILL JUMP SAME WAY as awin, prfx abos
THER CANCER TESTS AND TREATMENT OPTIONS
THERALINK.COM
Going to be nasdaq merger with BACK
THER STOCK..WILL JUMP SAME WAY as bbio, prfx
THER CANCER TESTS AND TREATMENT OPTIONS
THERALINK.COM
Going to be nasdaq merger with BACK
THER STOCK..WILL JUMP SAME WAY as abos, prfx
THER CANCER TESTS AND TREATMENT OPTIONS
THERALINK.COM
Going to be nasdaq merger with BACK
THER STOCK..WILL JUMP SAME WAY
THER CANCER TESTS AND TREATMENT OPTIONS
THERALINK.COM
Going to be nasdaq merger with BACK
THER STOCK..WILL JUMP SAME WAY
THER CANCER TESTS AND TREATMENT OPTIONS
THERALINK.COM
Going to be nasdaq merger with BACK
THER STOCK..WILL JUMP SAME WAY
THER CANCER TESTS AND TREATMENT OPTIONS
THERALINK.COM
Going to be nasdaq merger with BACK
Check tomm. You would cry.
Why u waste ur time here on this board when you have no idea where this can reach.
prfx can go up to 100$ tomm
THER STOCK..WILL JUMP SAME WAY
THER CANCER TESTS AND TREATMENT OPTIONS
THERALINK.COM
You are still buying it this stock? And tell all negative, i know what you are up
Another big run for SMX
Same like grrr
Strong buy
with Ther merger this can go to 1$
Buy ther
Once in nasdaq this can go to 1$
Cancer treatment and tests
Big pharma can use this technology for
Treatment options
Good news we have a great team !!
pbts vs ther
Ther so many good news..reddit stock
https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html
ttoo vs ther
Ther stock buy now..reddit stock
Will be merger or buyout
https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html
wnw vs ther
Ther reddit news..buy now before explode
https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html
jspr vs ther
Strong buy ther
Reddit stock news
https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html
nvos vs ther
Buy ther..so many good news
Reddit stock
https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html
nutx vs ther
Ther stock can go back to 1$
Buy ther..good news
https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html
buy Ther
Theralink.com
Cancer test and treatment options
52 week it was 2$
pali vs ther
Strong buy ther
Ther stock good news..will go back to .10 soon
Theralink Technologies is a precision medicine company with a nationally CLIA-certified and CAP-accredited laboratory in Golden, Colorado. Theralink’s unique and patented Reverse Phase Protein Array (RPPA) technology platform can quantify protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. Since protein signaling is responsible for the development and progression of cancer, nearly all FDA-approved cancer therapeutics target proteins, not genes. The Theralink® RPPA technology can reveal the protein drug target(s) that are essentially turned “on” in a patient’s cancer and suggest the most effective treatment plan to turn those proteins “off”. Therefore, the Theralink® RPPA technology is a critical tool that empowers oncologists with actionable information to effectively treat a cancer patient, which is often missed by standard proteomic and genomic testing.
Our commercially available Lab Developed Test (LDT), the Theralink® Assay for Breast Cancer, is currently being utilized by oncologists across the United States to assist in making the most targeted treatment plan for their patients with advanced breast cancer. In 2023, Theralink began receiving reimbursement for this test by Medicare and certain third-party payors. The Theralink® test determines which drug target(s) are present and/or activated to reveal to the oncologist which patients are predicted to be responders versus non-responders to a particular therapeutic. The test provides therapeutic recommendations to support oncologist treatment selection of the best therapy option – which may improve patient response and consequently save the healthcare system
Treatment options for other cancers too
xela vs ther
Ther stock with so many good news
Theralink Technologies is a precision medicine company with a nationally CLIA-certified and CAP-accredited laboratory in Golden, Colorado. Theralink’s unique and patented Reverse Phase Protein Array (RPPA) technology platform can quantify protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. Since protein signaling is responsible for the development and progression of cancer, nearly all FDA-approved cancer therapeutics target proteins, not genes. The Theralink® RPPA technology can reveal the protein drug target(s) that are essentially turned “on” in a patient’s cancer and suggest the most effective treatment plan to turn those proteins “off”. Therefore, the Theralink® RPPA technology is a critical tool that empowers oncologists with actionable information to effectively treat a cancer patient, which is often missed by standard proteomic and genomic testing.
Our commercially available Lab Developed Test (LDT), the Theralink® Assay for Breast Cancer, is currently being utilized by oncologists across the United States to assist in making the most targeted treatment plan for their patients with advanced breast cancer. In 2023, Theralink began receiving reimbursement for this test by Medicare and certain third-party payors. The Theralink® test determines which drug target(s) are present and/or activated to reveal to the oncologist which patients are predicted to be responders versus non-responders to a particular therapeutic. The test provides therapeutic recommendations to support oncologist treatment selection of the best therapy option – which may improve patient response and consequently save the healthcare system
Good news coming..its going to go back tp $$$
Ther meme stock
THER vs pbts
Ther so many good news, can be take over with big pharma for cancer treatment options and tests
https://www.prnewswire.com/news-releases/theralink-technologies-begins-receiving-payments-from-third-party-payors-for-its-advanced-breast-cancer-assay-achieving-key-milestone-301753997.html
Ther meme stock
THER stock Good news going back to 1$ like top, megl
https://www.prnewswire.com/news-releases/theralink-technologies-begins-receiving-payments-from-third-party-payors-for-its-advanced-breast-cancer-assay-achieving-key-milestone-301753997.html
Ther good news .
Cancer treatment and options
THER MEME stck
https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html
Ther good news..on cancer treatments and tests
Ther meme stock
https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html
Ther Vs ctxr
Ther good news on cancer csn jump back to 52 week high
https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html
Ther buy now with cancer good news
THER MEME STOCK
https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html
THER STOCK CANCER GOOD NEWS
BUY Ther
.meme stock
https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html